Scholarlink

Background <p>This meta-analysis evaluates the diagnostic and staging accuracy of [<sup>18</sup>F]F-FES PET/CT, its ability to detect estrogen receptor (ER) positivity, and its effectiveness in predicting response to endocrine therapy in ER-positive (ER+) breast cancer. A systematic search of PubMed, Embase (OVID), and Web of Science databases was conducted for studies published between 2013 and June 2024. Studies involving ER + breast cancer patients who underwent</p> <p>[<sup>18</sup>F]F-FES PET/CT were included. We analyzed the diagnostic accuracy, ER detection capability, and predictive ability for endocrine therapy response.</p> Results <p>Out of 189 studies initially identified, 21 met the inclusion criteria. For diagnosis and staging compared to [<sup>18</sup>F]F-FDG PET (10 studies), [<sup>18</sup>F]F-FES PET/CT demonstrated a sensitivity of 0.75 (95% CI: 0.62–0.85) and a false positive rate (FPR) of 0.27 (95% CI: 0.09–0.50). For ER detection (7 studies), sensitivity was 0.86 (95% CI: 0.71–0.94) with an FPR of 0.45 (95% CI: 0.19–0.73). For predicting response to endocrine therapy (12 studies), [<sup>18</sup>F]F-FES PET/CT showed a sensitivity of 0.79 (95% CI: 0.62–0.89) and an FPR of 0.58 (95% CI: 0.42–0.72).</p> Conclusions <p>[<sup>18</sup>F]F-FES PET/CT is valuable for diagnosing and staging ER + breast cancer, assessing ER status, and predicting response to endocrine therapy. Its implementation can improve treatment planning and patient outcomes in breast cancer management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

[18F]F-FES PET for diagnosis, staging, and endocrine therapy prediction in ER-positive breast cancer: a systematic review and meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年2月27日

查看全文
  • Ying Xu,
  • Ru Yao,
  • Zhixin Hao,
  • Fangyuan Chen,
  • Bowen Liu,
  • Qiang Sun,
  • Bo Pan,
  • Li Huo,
  • Yidong Zhou

摘要

Background

This meta-analysis evaluates the diagnostic and staging accuracy of [18F]F-FES PET/CT, its ability to detect estrogen receptor (ER) positivity, and its effectiveness in predicting response to endocrine therapy in ER-positive (ER+) breast cancer. A systematic search of PubMed, Embase (OVID), and Web of Science databases was conducted for studies published between 2013 and June 2024. Studies involving ER + breast cancer patients who underwent

[18F]F-FES PET/CT were included. We analyzed the diagnostic accuracy, ER detection capability, and predictive ability for endocrine therapy response.

Results

Out of 189 studies initially identified, 21 met the inclusion criteria. For diagnosis and staging compared to [18F]F-FDG PET (10 studies), [18F]F-FES PET/CT demonstrated a sensitivity of 0.75 (95% CI: 0.62–0.85) and a false positive rate (FPR) of 0.27 (95% CI: 0.09–0.50). For ER detection (7 studies), sensitivity was 0.86 (95% CI: 0.71–0.94) with an FPR of 0.45 (95% CI: 0.19–0.73). For predicting response to endocrine therapy (12 studies), [18F]F-FES PET/CT showed a sensitivity of 0.79 (95% CI: 0.62–0.89) and an FPR of 0.58 (95% CI: 0.42–0.72).

Conclusions

[18F]F-FES PET/CT is valuable for diagnosing and staging ER + breast cancer, assessing ER status, and predicting response to endocrine therapy. Its implementation can improve treatment planning and patient outcomes in breast cancer management.